Sadushi-Kolici, Roela <br/><br/>
Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.  [electronic resource] 

 -  The Lancet. Respiratory medicine  03 2019 
 - 239-248 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2213-2619 
<br/><br/><label>Standard No.: </label>10.1016/S2213-2600(18)30367-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antihypertensive Agents--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Monitoring--methods<br/>Epoprostenol--administration & dosage<br/>Exercise Tolerance--drug effects<br/>Female<br/>Humans<br/>Hypertension, Pulmonary--diagnosis<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged<br/>Pulmonary Embolism--complications<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Walk Test--methods